Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.

Szczegóły
Comments

Tytuł:: Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.
Autorzy:: Gade AR; Internal Medicine Residency Program, Department of Medicine, Medical City Fort Worth, Fort Worth, Texas, USA.
Alavala H; Division of Transplant Nephrology, Tarrant Nephrology Associates/Premier Physicians Group Health, Fort Worth, Texas, USA.
Allam SR; Division of Transplant Nephrology, Tarrant Nephrology Associates/Premier Physicians Group Health, Fort Worth, Texas, USA. Electronic address: .
Źródło:: Kidney international [Kidney Int] 2020 Oct; Vol. 98 (4), pp. 1054. Date of Electronic Publication: 2020 Jul 08.
Typ publikacji:: Letter; Comment
Język:: English
Imprint Name(s):: Publication: 2016- : New York : Elsevier
Original Publication: New York, Springer-Verlag.
MeSH Terms:: Coronavirus Infections*
Interleukin-6*
Kidney Transplantation*
Pandemics*
Pneumonia, Viral*
Antibodies, Monoclonal, Humanized ; Betacoronavirus ; COVID-19 ; Cytokine Release Syndrome ; Humans ; SARS-CoV-2 ; Transplant Recipients
References:: Blood. 2008 Nov 15;112(10):3959-64. (PMID: 18784373)
J Rheumatol. 2013 Jul;40(7):1074-81. (PMID: 23637318)
Transpl Infect Dis. 2020 Aug;22(4):e13326. (PMID: 32406985)
Kidney Int. 2020 Aug;98(2):508-509. (PMID: 32505467)
Substance Nomenclature:: 0 (Antibodies, Monoclonal, Humanized)
0 (Interleukin-6)
I031V2H011 (tocilizumab)
Entry Date(s):: Date Created: 20200711 Date Completed: 20201005 Latest Revision: 20210110
Update Code:: 20240105
PubMed Central ID:: PMC7340591
DOI:: 10.1016/j.kint.2020.06.025
PMID:: 32650019
: Opinia redakcyjna

Comment on: Kidney Int. 2020 Aug;98(2):508-509. (PMID: 32505467)

Informacja